



Sheet 1 of 1

FORM PTO-1449  
PARENT & TRADEMARKS

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:  
**IN01174**

SERIAL NO.:  
**10/013,071**

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

APPLICANT:  
**Zhu et al.**

FILING DATE:  
**12/10/2001**

GROUP:  
**1614**

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO
AL							
AM							
AN							
AO							
AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

RJ	AQ	Llinas-Brunet et al.: "Studies on the C-Terminal of Hexapeptide Inhibitors of the Hepatitis C Virus Serine Protease" <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , Oxford, GB, 8(19):2719-2724 (1998)
	AR	
	AS	
	AT	
	AU	
	AV	

EXAMINER RJ	DATE CONSIDERED 04-01-04
----------------	-----------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APR 25 2002

APR 29 2002

Sheet 1 of 1  
TECH CENTER 1600/2900

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.: IN01174  
SERIAL NO.: 10/013,071APPLICANT  
Zhu, et alFILING DATE: December 10, 2001  
GROUP: 1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
AA	U.S. 5,712,145					
AB						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES    NO
AC	WO 89/04669					
AD	WO 98/17679					
AE	WO 98/22496					
AF	WO 98/07734					
AG	WO 00/09558					
AH	WO 00/09543					
AI	EP 381 216					
AJ						
AK						

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AL	Pizzi, (1994) Proc. Natl. Acad. Sci(USA) 91:888-892
AM	Failla (1996) folding & Design 1:35-42
AN	Kollykhalov (1994) J. Virol. 68:7525-7533
AO	Komoda (1994) J. Virol. 68:7351-7357
AP	Landro (1997) Biochem 36:9340-9348
AQ	Ingallinella (1998) Biochem 37:8906-8914
AR	Llinas-Brunet (1998) Bioorg. Med. Chem. Lett. 8:1713-1718
AS	Martin (1998) Biochem 37:11459-11468
AT	Dimasi (1997) J. Virol. 71:7461-7469
AU	Martin (1997) Protein Eng. 10:607-614
AV	Elzouki (1997) J. Hepat. 27:42-48
AW	Bio World Today 9(217): 4 (November 10, 1998)
AX	Berenguer (1998) Proc. Assoc. Am. Physicians 110(2): 98-112
AY	Hoofnagle (1997) New England Journal Med. 336:347
AZ	Zhang (199) Analytical Biochemistry 270:268-275
BA	Sali (1998) Biochemistry 3392-3401
BB	Barlos (1991) Int. J. Pept. Protein Res 513-520
BC	Holmberg (1979) Acta Chem. Scand., B33:410-412
BD	Agrawal(1999) Hepatology Supplement to Vol 30 "Development and Characterization of Hepatitis C Virus Serine Protease Cell-based Trans-Cleavage Assay"
BE	Hughes (1992) Org. Reactions 42:335
BF	Heck (1989) Org. Reactions 27:345-390
BG	Han, (2000) Bioorganic & Medicinal Chemistry Letters 10 "α-Ketoamides, α-Ketoesters and α-Ketones as HCV NS3 Protease Inhibitors" pp. 711-713.
BH	Marchetti(1999)Synlett, Vol. S1, "Synthesis of Two Novel Cyclic Biphenyl Ether Analogs of an Inhibitor of HCV NS3 Protease", pp 1000-1002.

EXAMINER

RB M

DATE CONSIDERED

04-01-04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.